Loading patent…
AssigneeVitrisa Therapeutics, Inc.
InventorsCarl ERICKSON, Christopher P. RUSCONI, Arijit BHOWMICK, Matthew LEVY, Matthew WALKER, Kevin G. MCLURE
Estimating the term…
The application discloses methods and compositions for inhibiting functions associated with Interleukin-8 (IL8). The methods and compositions may involve the use of aptamers for binding to IL8 and preventing or reducing association of IL8 with CXCR1, CXCR2, or both. The methods and compositions may include one or more aptamers that bind to an N-terminal domain of IL8. The methods and compositions may include one or more aptamers that bind to a hydrophobic pocket of IL8. The methods and compositions may include one or more aptamers that bind to an N-loop of IL8. The methods and compositions may include one or more aptamers that bind to a GAG binding site of IL8. The application further provides anti-IL8 aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-IL8 aptamers may have a stem-loop secondary structure.
1-209. (canceled)
An aptamer that binds to and inhibits Interleukin-8 (IL8), comprising a secondary structure comprising at least one terminal loop comprising greater than three nucleotides, wherein said terminal loop selectively binds to an epitope of IL8, wherein said epitope is not a GAG-binding site.
A method of treating an ocular disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an aptamer comprising a secondary structure comprising at least one terminal loop comprising greater than three nucleotides, wherein said at least one terminal loop participates in binding of said aptamer to IL8, thereby treating said ocular disease or disorder.
A method for modulating Interleukin-8 (IL8) in a biological system, said method comprising:
Dependencies are inferred from the claim text.